Continuation of psychiatric medications during pregnancy.
J Matern Fetal Neonatal Med
; 36(1): 2171288, 2023 Dec.
Article
em En
| MEDLINE
| ID: mdl-36710395
ABSTRACT
Background:
While medications for anxiety and depression are commonly used in the United States, it is unclear to what degree they are continued during pregnancy.Methods:
We used a large administrative database to determine whether psychiatric medications are continued during pregnancy and predictors of continued medication treatment.Results:
Of 2,672,656 women included in our analysis, 86,454 (3.1%) filled a pre-pregnancy prescription for an anxiolytic or antidepressant medication within 3 months of estimated conception. Of women who filled a pre-pregnancy prescription, 49.4%, 26.1%, and 20.1% filled subsequent prescriptions in the 1st, 2nd, and 3rd trimesters. Discontinuation rates ranged by pharmaceutical agent, from 16% for fluoxetine to 71% for alprazolam. White women and women over 25 were more likely to continue anxiolytic and antidepressant treatment during pregnancy.Conclusion:
Because untreated and under-treated mental health conditions are linked to adverse maternal outcomes, high discontinuation rates may have important implications for maternal health.Palavras-chave
Texto completo:
1
Bases de dados:
MEDLINE
Assunto principal:
Complicações na Gravidez
/
Ansiolíticos
Tipo de estudo:
Prognostic_studies
Limite:
Female
/
Humans
/
Pregnancy
País/Região como assunto:
America do norte
Idioma:
En
Revista:
J Matern Fetal Neonatal Med
Assunto da revista:
OBSTETRICIA
/
PERINATOLOGIA
Ano de publicação:
2023
Tipo de documento:
Article
País de afiliação:
Estados Unidos